DK3079667T3 - Farmaceutiske doseringsformer - Google Patents

Farmaceutiske doseringsformer Download PDF

Info

Publication number
DK3079667T3
DK3079667T3 DK14819084.6T DK14819084T DK3079667T3 DK 3079667 T3 DK3079667 T3 DK 3079667T3 DK 14819084 T DK14819084 T DK 14819084T DK 3079667 T3 DK3079667 T3 DK 3079667T3
Authority
DK
Denmark
Prior art keywords
dosage forms
pharmaceutical dosage
pharmaceutical
forms
dosage
Prior art date
Application number
DK14819084.6T
Other languages
English (en)
Inventor
Suzie Ribeiro
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Application granted granted Critical
Publication of DK3079667T3 publication Critical patent/DK3079667T3/da

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38Cellulose; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0053Mouth and digestive tract, i.e. intraoral and peroral administration
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605Excipients; Inactive ingredients
    • A61K9/1629Organic macromolecular compounds
    • A61K9/1635Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605Excipients; Inactive ingredients
    • A61K9/1629Organic macromolecular compounds
    • A61K9/1652Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682Processes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4833Encapsulating processes; Filling of capsules
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841Filling excipients; Inactive ingredients
    • A61K9/4858Organic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841Filling excipients; Inactive ingredients
    • A61K9/4866Organic macromolecular compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
DK14819084.6T 2013-12-13 2014-12-11 Farmaceutiske doseringsformer DK3079667T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361915606P 2013-12-13 2013-12-13
PCT/IB2014/066820 WO2015087283A1 (en) 2013-12-13 2014-12-11 Pharmaceutical dosage forms

Publications (1)

Publication Number Publication Date
DK3079667T3 true DK3079667T3 (da) 2019-09-09

Family

ID=52146563

Family Applications (1)

Application Number Title Priority Date Filing Date
DK14819084.6T DK3079667T3 (da) 2013-12-13 2014-12-11 Farmaceutiske doseringsformer

Country Status (34)

Country Link
US (3) US10278969B2 (da)
EP (2) EP3079667B1 (da)
JP (2) JP6522619B2 (da)
KR (1) KR102349893B1 (da)
CN (2) CN116942629A (da)
AR (1) AR098716A1 (da)
AU (1) AU2014362999B2 (da)
CA (1) CA2930055C (da)
CL (1) CL2016001436A1 (da)
CY (1) CY1122063T1 (da)
DK (1) DK3079667T3 (da)
EA (1) EA036288B1 (da)
EC (1) ECSP16060194A (da)
ES (1) ES2745983T3 (da)
HK (1) HK1223833A1 (da)
HR (1) HRP20191691T1 (da)
HU (1) HUE045156T2 (da)
IL (1) IL245705B (da)
LT (1) LT3079667T (da)
MA (1) MA39175A1 (da)
MX (1) MX2016007652A (da)
MY (1) MY194303A (da)
NZ (2) NZ760002A (da)
PE (1) PE20160851A1 (da)
PH (1) PH12016501039A1 (da)
PL (1) PL3079667T3 (da)
PT (1) PT3079667T (da)
RS (1) RS59270B1 (da)
SG (1) SG10202104627UA (da)
SI (1) SI3079667T1 (da)
TN (1) TN2016000207A1 (da)
TW (2) TWI800759B (da)
WO (1) WO2015087283A1 (da)
ZA (1) ZA201603064B (da)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2930055C (en) 2013-12-13 2023-07-04 Novartis Ag Pharmaceutical dosage forms comprising protein kinase inhibitor
MA41611A (fr) * 2015-02-23 2018-01-02 Omthera Pharmaceuticals Inc Préparations en milli-capsules comprenant des acides gras polyinsaturés libres
EP3675827A1 (en) 2017-08-30 2020-07-08 Acadia Pharmaceuticals Inc. Formulations of pimavanserin
CN116887822A (zh) * 2020-12-18 2023-10-13 奎德治疗学股份有限公司 治疗软骨发育不全的方法

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0512324D0 (en) 2005-06-16 2005-07-27 Novartis Ag Organic compounds
NZ591443A (en) 2005-09-22 2013-04-26 Intermune Inc Granule formation of pirfenidone and pharmaceutically acceptable excipients
JP5153645B2 (ja) 2005-12-21 2013-02-27 ノバルティス アーゲー Fgf阻害剤であるピリミジニルアリールウレア誘導体
FR2910813B1 (fr) * 2006-12-28 2009-02-06 Sanofi Aventis Sa Nouvelle utilisation therapeutique pour le traitement des leucemies
AR079257A1 (es) * 2009-12-07 2012-01-04 Novartis Ag Formas cristalinas de 3-(2,6-dicloro-3-5-dimetoxi-fenil)-1-{6-[4-(4-etil-piperazin-1-il)-fenil-amino]-pirimidin-4-il}-1-metil-urea y sales de las mismas
CA2840620A1 (en) 2011-07-01 2013-01-10 Novartis Ag Combination therapy
JP2016523973A (ja) 2013-07-09 2016-08-12 デイナ ファーバー キャンサー インスティチュート,インコーポレイテッド 疾患の処置のためのキナーゼ阻害物質
CA2930055C (en) 2013-12-13 2023-07-04 Novartis Ag Pharmaceutical dosage forms comprising protein kinase inhibitor
EP3659621A1 (en) 2014-09-13 2020-06-03 Novartis AG Combination therapies for cancer
WO2016151501A1 (en) 2015-03-25 2016-09-29 Novartis Ag Pharmaceutical combinations
US10702527B2 (en) 2015-06-12 2020-07-07 Dana-Farber Cancer Institute, Inc. Combination therapy of transcription inhibitors and kinase inhibitors

Also Published As

Publication number Publication date
PT3079667T (pt) 2019-10-10
NZ719865A (en) 2022-07-29
SG10202104627UA (en) 2021-06-29
US10278969B2 (en) 2019-05-07
TW201605494A (zh) 2016-02-16
EP3079667B1 (en) 2019-06-26
IL245705B (en) 2021-05-31
EA201691231A1 (ru) 2016-10-31
HRP20191691T1 (hr) 2019-12-27
TN2016000207A1 (en) 2017-10-06
CN116942629A (zh) 2023-10-27
EA036288B1 (ru) 2020-10-22
HUE045156T2 (hu) 2019-12-30
EP3079667A1 (en) 2016-10-19
CN105813635A (zh) 2016-07-27
WO2015087283A1 (en) 2015-06-18
TWI721938B (zh) 2021-03-21
AR098716A1 (es) 2016-06-08
CA2930055C (en) 2023-07-04
PL3079667T3 (pl) 2020-02-28
US20170007602A1 (en) 2017-01-12
ES2745983T3 (es) 2020-03-04
JP2019142927A (ja) 2019-08-29
KR20160096093A (ko) 2016-08-12
JP6804585B2 (ja) 2020-12-23
MX2016007652A (es) 2016-10-13
EP3597179A1 (en) 2020-01-22
ECSP16060194A (es) 2019-07-31
IL245705A0 (en) 2016-07-31
HK1223833A1 (zh) 2017-08-11
TW202128137A (zh) 2021-08-01
RS59270B1 (sr) 2019-10-31
JP6522619B2 (ja) 2019-05-29
NZ760002A (en) 2022-07-29
KR102349893B1 (ko) 2022-01-10
ZA201603064B (en) 2017-07-26
PE20160851A1 (es) 2016-09-14
US20200054632A1 (en) 2020-02-20
LT3079667T (lt) 2019-09-10
MA39175A1 (fr) 2017-10-31
AU2014362999A1 (en) 2016-05-26
US20220265651A1 (en) 2022-08-25
JP2017502941A (ja) 2017-01-26
CY1122063T1 (el) 2020-11-25
SI3079667T1 (sl) 2019-10-30
CL2016001436A1 (es) 2017-02-10
CA2930055A1 (en) 2015-06-18
TWI800759B (zh) 2023-05-01
AU2014362999B2 (en) 2017-10-12
EP3597179B1 (en) 2024-04-03
MY194303A (en) 2022-11-27
PH12016501039A1 (en) 2016-07-04
US11160804B2 (en) 2021-11-02

Similar Documents

Publication Publication Date Title
FR21C1059I2 (fr) Compositions pharmaceutiques
DK3030262T3 (da) Kombineret farmaceutisk sammensætning
BR112016009485A2 (pt) Inalador de medicamento
DK3062849T3 (da) Medikamentadministrationsanordning
DK3035991T3 (da) Lægemiddelleveringsindretninger med flere enheder
DK3038674T3 (da) Medikamentafgivelsesindretning
DOS2013000177S (es) Capsulas
DK3590499T3 (da) Inhalerbare lægemidler
UA29750S (uk) Інгалятор
DK3035886T3 (da) Inhalator
DK2964193T3 (da) Lægemidler til oral indgivelse
HK1223833A1 (zh) 藥物劑型
DK3003401T3 (da) Farmaceutisk præparat
DK2897588T3 (da) Inhalerbart lægemiddel
DK2983747T3 (da) Lægemiddelindgivelsesindretning
DK3043845T3 (da) Lægemiddelfremføringsanordning
DK2972363T3 (da) Immunpotenserende nanobærerlægemiddel
TH1601003393A (th) รูปแบบปริมาณที่ให้ทางเภสัชกรรม
DK3071261T3 (da) Lægemiddeladministrationsanordning
DK3071267T3 (da) Lægemiddeladministrationsanordning med ensrettet kobling
TH1401004646B (th) องค์ประกอบทางเภสัชกรรมชนิดรับประทาน
UA28330S (uk) Капсула для лікарського засобу
DK2945666T3 (da) Lægemiddelafgivelsesindretning
UA28963S (uk) Пляшечка на ліки
UA28964S (uk) Пляшечка на ліки